Table 1. MRC technology deals.

Year

Indication

Collaborator

Deal

Therapeutic modality

2012

Undisclosed

Shanghai Institute of Biochemistry and Cell Biology (SIBCB), part of the Chinese Academy of Sciences

SIBCB will share access to potential targets, which can be further developed at MRC Technology's Centre for Therapeutic Discovery

Small molecules

2012

Infectious disease, drug addiction and autoimmune disease

Mount Sinai School of Medicine

MRC Technology will humanize mouse antibodies created by Mount Sinai's Center for Therapeutic Antibody Discovery to control infection and treat disease

mAbs

2012

Undisclosed

Academic research institutes

MRC Technology will provide academic research institutes free access to a representative subset of 9,000 compounds in plate format from its library of 150,000 small molecules. MRC Technology will have a right of first refusal to partner on any resulting drug development programs and also will have joint ownership of any generated data

Small molecules

2012

Undisclosed

William Harvey Research Institute at Barts and The London School of Medicine and Dentistry

MRC Technology will screen and develop compounds to target G protein-coupled receptors

Small molecules

2010

Neurology

Roche's Genentech Inc. unit

MRC Technology granted Genentech exclusive rights to develop and commercialize a group of small molecule drug candidates for the potential treatment of neurological diseases. Medical Research Council (MRC) will receive an upfront payment and is eligible for milestones and royalties

Small molecules

2010

Cancer, cardiovascular disease, neurology and infection

AstraZeneca plc

MRC Technology will screen a compound library for five undisclosed targets from AstraZeneca in the areas of cancer, cardiovascular disease, neurology and infection and five additional targets from MRC for the same areas. The library includes 100,000 compounds from the pharma and 50,000 compounds from MRC. The partners will retain ownership of their respective compounds and plan to negotiate licenses for projects chosen for further development. The licenses would trigger option fees to MRC

Small molecules

2008

Lymphoma

Biolex Therapeutics Inc.

MRC Technology will humanize Biolex's BLX-301 antibody, which is an optimized glycosylated version of rituximab and is in preclinical development for non-Hodgkin's lymphoma. Biolex will retain full rights to the antibody, and MRC will be eligible for milestones and royalties

mAbs

2007

Alzheimer's disease (AD)

Intellect Neurosciences Inc.

MRC Technology has humanized two of Intellect's mAbs against b-amyloid (Ab) to treat AD and age-related macular degeneration (AMD). Intellect is working with Lonza Group Ltd. to manufacture humanized antibody and a humanized antibody conjugate, called conjumab A, for lead testing and optimization. MRC Technology is eligible for undisclosed milestones and royalties

mAbs

2007

Cancer

Akzo Nobel N.V.

MRC Technology will humanize an antibody from Akzo's Organon BioSciences N.V. unit to treat cancer. MRC Technologies is eligible for milestones and royalties. Organon has all rights to develop and commercialize the humanized antibody. Organon was acquired by Schering-Plough Corp. (now part of Merck & Co. Inc.)

mAbs